This debate about what the FDA has or hasn't seen is

New Post Public Reply Private Reply Replies (0) Message Board
JLang
998
This debate about what the FDA has or hasn't seen is neglecting the most significant (and absolutely certain) information we all know has been sitting on their desks for years: safety.

They know it's safe. Hundreds of HIV patients, over years can attest to that. "Safer than placebo" results in CD10 / Mild & Moderate Covid proved that. (That's code for "efficacy".

Safety will not be an issue in the slightest, as evidenced by the resumption of eINDs and the green light for trial sites to continue to administer Leronlimab to severe & critical Covid patients, past full enrollment. The FDA won't do that just for shits and giggles.

Manufacturing can't be an issue... What we have is all there is and it's all needed. It's the only tool that can be brought to beat on severe / critical, other than dex and ventilators/HFNC. We all know how well those are working.

It's proven safe. If it has even a mild, 10% or so benefit to mortality, it's golden. If it reduces LH symptom severity or hastens time to improvement, it'll get EUA or approval.

Odds that neither will apply are rapidly dwindling.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Winning Strategies for Sales Teams: Ebsta’s Insights Unveiled

Updated Category News Views 128

Winning Strategies for Sales Teams: Ebsta’s Insights Unveiled In today's competitive landscape, sales teams are continually seeking ways to outperform their competition. A recent comprehensive report from the revenue intelligence company Ebsta highlights groundbreaking findings on what sets top-performing sales teams apart. This study reveals that effective...

Continue Reading
Investigation into Cardlytics: What Investors Need to Know

Updated Category News Views 264

Understanding the Investigation into Cardlytics Faruqi & Faruqi, LLP, a recognized leader in securities litigation, is actively investigating potential claims on behalf of investors who may have suffered losses while investing in Cardlytics, Inc. (NASDAQ: CDLX). This inquiry aims to clarify the missteps taken by the company and to uphold the rights of its shareholders....

Continue Reading
GIGABYTE Launches Innovative QD-OLED Monitors Redefining Gaming

Updated Category News Views 403

GIGABYTE Introduces Cutting-Edge QD-OLED Monitors GIGABYTE, renowned as a leader in computer technology, has unveiled two revolutionary QD-OLED monitors that are set to transform the gaming and professional display landscape. The AORUS FO27Q5P and GIGABYTE MO27U2 are equipped with extraordinary features that provide unmatchable clarity and swift performance, catering to...

Continue Reading
Key Financial Insights from OPEC and Fed Speech Planned

Updated Category News Views 65

Analyzing Upcoming Financial Events Traders are gearing up for an important day in the financial markets. The focus is set on crucial reports and speeches that can significantly influence market behavior. Key among these events are the OPEC Monthly Report and the anticipated speech from Federal Reserve Governor Christopher Waller. What to Expect from the OPEC Monthly...

Continue Reading
Vestis Corporation Investors Urged to Take Action Now

Updated Category News Views 148

Important Announcement for Vestis Corporation Investors If you've invested in Vestis Corporation (NYSE: VSTS), it's crucial to stay informed about the potential legal actions unfolding due to significant allegations about the company's operations. Why Legal Counsel is Essential Under a contingency fee arrangement, investors who purchased securities between May 2, 2024,...

Continue Reading